The Food and Drug Administration has now classified a manufacturing defect in catheter introducer kits used with Impella heart pumps as a Class I recall, the agency's most serious category, roughly three weeks after it first warned the public through a preliminary notice.
Federal records show 13 separate recall entries tied to a single event, all posted on the same day and all assigned Class I status. The recall covers introducer kits made by Oscor for Johnson & Johnson's Abiomed unit in 14 French and 23 French sizes, sold both individually and packaged inside Impella pump sets distributed across the United States and roughly three dozen other countries.
For families, the practical meaning is narrow but serious. These devices are not used at home. They are used in hospital catheterization labs and cardiac intensive care units on people who are often in cardiogenic shock or undergoing high-risk coronary procedures. If a relative is scheduled for or currently receiving temporary heart pump support in a U.S. hospital, the recall is a reasonable thing to ask the care team about, and the FDA has not told hospitals to stop using the equipment.
Inside the Gap Between an Early Alert and a Classified Recall
The agency's Early Alert on the introducer issue appeared in mid June, days after the manufacturers wrote to hospitals. An Early Alert is a comparatively new communication tool. The FDA uses it to flag a potentially high-risk device problem while its own review is still underway, rather than waiting for the classification process to conclude. The agency explains the mechanism on its Early Alert reference page.
Classification is the next step. Once the FDA finished evaluating the health hazard, it assigned the action a class. Class I means the agency concluded that use of the affected product could cause serious injury or death. The recall database entry for one of the affected kits carries recall number Z-2684-2026 and lists the action as a correction rather than a product removal, meaning the devices stay in hospitals under revised handling instructions.
That distinction matters for patients. A Class I designation describes the severity of the potential hazard. It does not automatically mean the product is being pulled from shelves, and in this case it is not.
The Bleeding Mechanism Hospitals Were Asked to Watch For
Abiomed identified a potential for the introducer sheath to leak at the sidearm, beneath the sheath cap, and along score lines in the hub region. The FDA attributes the problem to manufacturing issues. Because these introducers are used for large-bore vascular access, often in patients receiving blood thinners, an undetected leak can become significant quickly.
The agency's alert describes blood loss that may require manual compression, device exchange or removal, and in some cases transfusion. In patients with limited physiologic reserve, the FDA said exposure to the hazard could contribute to life-threatening hemorrhage and hemodynamic instability.
The recall record notes that the manufacturing flaw is "not visually detectable by the user," which is why the FDA is relying on clinical monitoring rather than visual inspection of inventory.
As of April 22, Abiomed had reported eight instances of major bleeding. Three complaints had corresponding patient deaths. The company determined that those deaths were not attributable to introducer leakage. The FDA has not published an independent conclusion on causation, and that assessment remains one of the open questions in this case.
Instructions Hospitals Received, and What Has Not Changed
The manufacturers' letter did not tell hospitals to quarantine stock. The FDA's summary of the recommended actions opens with a line clinicians would have noticed immediately: "Hospitals may continue to use existing inventory."
Physicians were asked to maintain clinical awareness and monitoring, and to consider a device exchange or use of the repositioning sheath if leakage appears at the sidearm, under the sheath cap, or along the hub score lines. Facilities were told to circulate the notice to anyone who stores, transports, or uses the products, and to contact any downstream facility that received them.
The American Hospital Association flagged the introducer alert to member hospitals alongside a separate Class I recall involving Impella controllers, one of several device notices affecting the same product family this year. Trade coverage from MedTech Dive noted that the introducer action followed a string of Impella-related regulatory notices in 2026.
Questions Worth Raising Before a Scheduled Cardiac Procedure
This is not a situation calling for individual action by most readers. Nobody has an introducer kit at home, and no patient can check a lot number themselves.
Patients or family members facing a planned high-risk percutaneous coronary intervention, or supporting a relative already on temporary mechanical circulatory support, can reasonably ask the cardiology team three things. Whether the hospital received the manufacturers' notice. Whether the facility has adjusted its access-site monitoring protocol. And what signs the team watches for at the insertion site during and after the procedure.
Nobody should delay or decline urgent cardiac care based on a device recall. Impella support is used in situations where the alternative is often worse, and the FDA has not restricted its use. Any decision about a specific procedure belongs with the treating clinician.
Clinicians and consumers who experience a problem can report it through the FDA's MedWatch program. The FDA has said it will keep updating its alert page as significant new information becomes available, and the recall remains open, meaning not all affected product has been corrected. Whether the agency revises its assessment of the three reported deaths is the most consequential unresolved item.
Frequently Asked Questions
What exactly was recalled? Catheter introducer kits in 14 French and 23 French sizes, made by Oscor for Abiomed and used to insert Impella heart pumps. They were sold individually and inside Impella pump sets.
Does Class I mean the devices are being removed from hospitals? No. The FDA classified this as a correction. Class I describes the severity of the potential hazard, not the type of action. Hospitals were told they may keep using existing inventory with added monitoring.
How is an Early Alert different from a recall? An Early Alert is a preliminary public notice the FDA issues while it is still reviewing a potentially high-risk device problem. Classification as Class I, II or III comes after that review concludes.
Were any deaths caused by this defect? Three complaints had corresponding patient deaths, and Abiomed determined the deaths were not attributable to introducer leakage. The FDA has not published a separate causation finding.
Should a patient postpone a heart procedure because of this? No. The FDA has not restricted use of these devices. Decisions about cardiac procedures should be made with the treating cardiologist, who can address facility-specific monitoring.
How would a leak be detected during a procedure? Clinicians are advised to watch for blood loss at the sidearm and hub of the introducer sheath, and to consider a device exchange or repositioning sheath if leakage appears.
Where can problems with the device be reported? Health care professionals and consumers can submit reports through the FDA's MedWatch adverse event reporting program.
